ID | 1167 |
Name of the vaccine | Pediacel |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | Over 6 weeks |
Description of the vaccine | Diphtheria, tetanus toxoids, acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine and haemophilus b conjugate vaccine
(Tetanus protein conjugate). |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 2004 |
Clinical Phase status | Approved |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | The anti-PRP seroprotection rate (antibody concentration over 0.15 mg/mL) was 67.7% after a two or three dose primary series. |
Vaccine formulation | White to off-white suspension for injection |
Dosage | Primary vaccination: Two or three dose series, gap of at least 1 month.
Booster vaccination: Single dose, 6 months after the last dose. |
Mechanism of action | T-dependent immune response with induction of immunological priming and memory. |
Route of administration | Intramuscular |
Indications | Immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b disease. |
Export | EU marketing authorisation |
Approval | NA |
Adjuvant | Aluminium phosphate |
Repurposing | For diphtheria, tetanus, pertussis, poliomyelitis and Hib. |
Side effects of vaccine | Redness, swelling or tenderness, irritability, less activity, vomiting, unusual high-pitched crying, fever, appetite loss, diarrhoea. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 21999652 |
Clinical trial number | NA |
Reference | NA |
Other name | NA |
Additional Links | https://pdf.hres.ca/dpd_pm/00015723.PDF
|